Q-omics provides the consensus-scored MAPK7 profile across patient tissues and cancer cell-line models. MAPK7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAPK7 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, MAPK7 RNA expression shows 19,608 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, and KIRP as cancer lineages where MAPK7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK7 survival associations across molecular data types. MAPK7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK7 RNA expression–survival associations across cancer types. High MAPK7 expression shows unfavorable associations in ACC, LIHC, LUAD and LGG, but favorable associations in UCS and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAPK7 RNA expression.
This table summarizes MAPK7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAPK7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK7 shows lower tumor expression in KICH and COAD and higher tumor expression in KIRP, KIRC, LIHC and CHOL. The KIRP box plot shows higher MAPK7 RNA expression in tumor versus normal tissue (log2 FC = +0.782, t-test p < 0.001).
This table shows molecular features associated with MAPK7 in patient tissues and cancer cell lines. In patient samples, MAPK7 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPK7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
